Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications

References

• Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000;356:1795–9.
   PubMed Web of Science ®Google Scholar
• Piroozmand A, Hassan ZM. Evaluation of natural killer cell activity in pre and post treated breast cancer patients. J Cancer Res Ther. 2010;6:478–81.
   PubMedGoogle Scholar
• Dewan MZ, Takada M, Terunuma H, Deng X, Ahmed S, Yamamoto N, . Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients. Biomed Pharmacother. 2009;63:703–6.
   PubMed Web of Science ®Google Scholar
• Kondo E, Koda K, Takiguchi N, Oda K, Seike K, Ishizuka M, . Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig Surg. 2003;20:445–51.
   Google Scholar
• Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Xiangming C, Iwashige H, . Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. Cancer Lett. 2000;159:103–8.
   Google Scholar
• Sconocchia G, Zlobec I, Lugli A, Calabrese D, Iezzi G, Karamitopoulou E, . Tumor infiltration by FcgammaRIII (CD16) + myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int J Cancer. 2011;128:2663–72.
   PubMedGoogle Scholar
• Al-Shibli K, Al-Saad S, Donnem T, Persson M, Bremnes RM, Busund LT. The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology. 2009;55:301–12.
   PubMed Web of Science ®Google Scholar
• Villegas FR, Coca S, Villarrubia VG, Jimenez R, Chillon MJ, Jareno J, . Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer. 2002;35:23–8.
   PubMed Web of Science ®Google Scholar
• Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol. 2008;9:486–94.
   PubMed Web of Science ®Google Scholar
• Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, . Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051–7.
   PubMed Web of Science ®Google Scholar
• Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, . Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy. 2008;10:625–32.
   PubMed Web of Science ®Google Scholar
• Naume B, Gately M, Espevik T. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56 + NK cells. J Immunol. 1992;148:2429–36.
   PubMed Web of Science ®Google Scholar
• Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, Lai CF, . A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest. 1997;99:937–43.
   PubMed Web of Science ®Google Scholar
• Robertson MJ, Cameron C, Lazo S, Cochran KJ, Voss SD, Ritz J. Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals. Nat Immun. 1996;15:213–26.
   Google Scholar
• Perussia B, Ramoni C, Anegon I, Cuturi MC, Faust J, Trinchieri G. Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines. Nat Immun Cell Growth Regul. 1987;6:171–88.
   PubMedGoogle Scholar
• Miller JS, Oelkers S, Verfaillie C, McGlave P. Role of monocytes in the expansion of human activated natural killer cells. Blood. 1992;80:2221–9.
   PubMed Web of Science ®Google Scholar
• Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106: 376–83.
   PubMed Web of Science ®Google Scholar
• Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, . Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009;69:4010–7.
   PubMed Web of Science ®Google Scholar
• Vera JF, Brenner LJ, Gerdemann U, Ngo MC, Sili U, Liu H, . Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother. 2010;33: 305–15.
   PubMed Web of Science ®Google Scholar
• Lapteva N, Vera JF. Optimization manufacture of virus- and tumor-specific T cells. Stem Cells Int;2011:434392.
   Google Scholar
• Garg TK, Szmania SM, Khan JA, Hoering A, Malbrough PA, Moreno-Bost A, . Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica. 2012; in press.
   Google Scholar
• Garson D, Dokhelar MC, Wakasugi H, Mishal Z, Tursz T. HLA class-I and class-II antigen expression by human leukemic K562 cells and by Burkitt-K562 hybrids: modulation by differentiation inducers and interferon. Exp Hematol. 1985;13:885–90.
   Google Scholar
• Chen E, Karr RW, Frost JP, Gonwa TA, Ginder GD. Gamma interferon and 5-azacytidine cause transcriptional elevation of class I major histocompatibility complex gene expression in K562 leukemia cells in the absence of differentiation. Mol Cell Biol. 1986;6:1698–705.
   PubMed Web of Science ®Google Scholar
• Sutherland J, Mannoni P, Rosa F, Huyat D, Turner AR, Fellous M. Induction of the expression of HLA class I antigens on K562 by interferons and sodium butyrate. Hum Immunol. 1985;12:65–73.
   PubMed Web of Science ®Google Scholar
• Takemura Y, Koide Y, Kawabata M, Kitajima S, Ohba C, Suzuki H, . Synergistic enhancement of class I major histocompatibility complex antigen expression in K562 cells induced by recombinant human interferon-gamma and tumor necrosis factor in combination. Exp Hematol. 1989;17: 795–9.
   Google Scholar
• Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, de Witte, . Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One. 2011;6:e20740.
   PubMed Web of Science ®Google Scholar
• Sutlu T, Stellan B, Gilljam M, Quezada HC, Nahi H, Gahrton G, . Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy. 2010;12:1044–55.
   PubMed Web of Science ®Google Scholar
• Shimasaki N, Fujisaki H, Cho D, Masselli M, Lockey T, Eldridge P, . A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy. 2012;14:830–40.
   PubMed Web of Science ®Google Scholar
• Klingemann HG, Martinson J. Ex vivo expansion of natural killer cells for clinical applications. Cytotherapy. 2004;6: 15–22.
   PubMed Web of Science ®Google Scholar
• Koehl U, Esser R, Zimmermann S, Tonn T, Kotchetkov R, Bartling T, . Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klin Padiatr. 2005;217:345–50.
   PubMed Web of Science ®Google Scholar
• Decot V, Voillard L, Latger-Cannard V, Aissi-Rothe L, Perrier P, Stoltz JF, . Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression. Exp Hematol. 2010;38: 351–62.
   PubMed Web of Science ®Google Scholar
• Siegler U, Meyer-Monard S, Jorger S, Stern M, Tichelli A, Gratwohl A, . Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients. Cytotherapy. 2010;12:750–63.
   PubMed Web of Science ®Google Scholar
• McKenna DH Jr, Sumstad D, Bostrom N, Kadidlo DM, Fautsch S, McNearney S, . Good manufacturing practice production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion. 2007;47: 520–8.
   PubMedGoogle Scholar
• Carlens S, Gilljam M, Chambers BJ, Aschan J, Guven H, Ljunggren HG, . A new method for in vitro expansion of cytotoxic human CD3– CD56+ natural killer cells. Hum Immunol. 2001;62:1092–8.
   Google Scholar
• Suck G, Oei VY, Linn YC, Ho SH, Chu S, Choong A, . Interleukin-15 supports generation of highly potent clinical-grade natural killer cells in long-term cultures for targeting hematological malignancies. Exp Hematol. 2011;39: 904–14.
   Google Scholar
• Somanchi SS, Senyukov VV, Denman CJ, Lee DA. Expansion, purification, and functional assessment of human peripheral blood NK cells. J Vis Exp. 2011.
   PubMedGoogle Scholar
• Alici E, Sutlu T, Bjorkstrand B, Gilljam M, Stellan B, Nahi H, . Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood. 2008;111:3155–62.
   PubMed Web of Science ®Google Scholar
• Lee DA, Verneris MR, Campana D. Acquisition, preparation, and functional assessment of human NK cells for adoptive immunotherapy. Methods Mol Biol. 2010;651:61–77.
   PubMedGoogle Scholar